Vancomycin-Siderophore Conjugates for Gram-Negative Membrane Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The emergence of antimicrobial resistance, particularly in Gram-negative bacteria, poses a significant challenge due to the outer membrane barrier hindering antibiotic penetration, necessitating the development of novel antibiotics to combat infections effectively.
Innovation Solution
Vancomycin-siderophore conjugates are designed to penetrate the Gram-negative outer membrane via active uptake by the iron transport system, converting vancomycin into a broad-spectrum antibiotic effective against both Gram-negative and Gram-positive bacteria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If vancomycin is used as a traditional glycopeptide antibiotic, then it is effective against Gram-positive bacteria, but it cannot penetrate the outer membrane of Gram-negative bacteria
Solution Approach 1:
The patent employs siderophores as intermediary molecules that facilitate the penetration of vancomycin into Gram-negative bacteria. The siderophore component acts as a carrier that can cross the outer membrane barrier, thereby enabling the vancomycin to reach its target in the periplasmic space. This resolves the contradiction by introducing a mediating substance that bridges the gap between the antibiotic and the bacterial cell interior.
Solution Approach 2:
The patent creates composite molecules by conjugating vancomycin with siderophores, forming a hybrid structure that combines the antibacterial activity of vancomycin with the membrane-penetrating capability of siderophores. This composite approach allows the resulting conjugate to simultaneously achieve broad-spectrum activity and effective penetration into Gram-negative bacteria.
2Reliability
If new antibiotics are developed to combat antimicrobial resistance, then treatment effectiveness improves, but the complexity of drug development increases
Solution Approach 1:
The patent applies the concept of drug repurposing by taking vancomycin, a glycopeptide antibiotic originally developed for Gram-positive bacteria, and modifying it to become effective against Gram-negative bacteria as well. This multi-functional approach allows a single antibiotic class to address multiple bacterial types, thereby improving treatment effectiveness while reducing the complexity of developing entirely new drugs.
Solution Approach 2:
The patent modifies the chemical structure of vancomycin by changing specific parameters (conjugating siderophore groups at defined positions) to alter its pharmacological properties. These parameter changes enable the antibiotic to penetrate Gram-negative outer membranes while maintaining its cell wall synthesis inhibition activity, thus achieving new therapeutic capabilities through structural modification rather than de novo development.
3Reliability
If the outer membrane barrier is overcome, then antibiotic penetration improves, but the risk of bacterial resistance increases
Solution Approach 1:
The patent introduces siderophore groups at specific local positions (C-1, C-6, or C-12) of the vancomycin molecule. This localized modification creates a specific penetration mechanism at the outer membrane without requiring changes to the entire antibiotic structure. The siderophore groups at these specific locations facilitate uptake while the rest of the vancomycin molecule maintains its original antibacterial mechanism, thereby improving penetration while limiting the spread of resistance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vancomycin-siderophore conjugates enhance antibiotic efficacy by bypassing the Gram-negative cell wall, providing a broad-spectrum treatment option for bacterial infections, including those caused by resistant pathogens.
Implementation Method 1
Vancomycin-siderophore conjugates are designed to penetrate the Gram-negative outer membrane via active uptake by the iron transport system
Implementation Method 2
Vancomycin binds to the D-Ala-D-Ala moiety of the bacterial cell wall precursor Lipid II to inhibit the subsequent transglycosylation and transpeptidation, leading to bacterial lysis and death
Data Source
AI summary
The present disclosure provides novel vancomycin derivatives that act as antimicrobials against Gram-negative bacteria. The compounds of the present disclosure are believed to be useful for the treatment of diseases caused by antimicrobial resistant bacteria, including Acinetobacter baumannii and Escherichia coli.